文献速递肺外科

胸腔镜手术与开胸手术治疗肺癌:一项随机试验的短期结局

Thoracoscopic Surgery Versus Thoracotomy for Lung Cancer: Short-Term Outcomes of a Randomized Trial.
PubMed 文献 · Ann Thorac Surg · 2017-12-02

该随机对照试验在五家三级医院纳入508例临床早期非小细胞肺癌患者,比较胸腔镜与腋下开胸行肺叶切除加纵隔淋巴结清扫的短期围术期结局。胸腔镜组手术时间中位数150分钟显著短于开胸组166分钟(p=0.009),且术中出血更少(p=0.001)。两组术后胸腔引流、住院时间、并发症与死亡率无差异,淋巴结获取数相似(p=0.389)。

要点

  • 胸腔镜肺叶切除治疗早期非小细胞肺癌安全可靠,手术时间和术中出血可能优于腋下开胸。
  • 胸腔镜组8例(3.72%)术中转为开胸。
  • 两组术后胸腔引流、住院时间、并发症与死亡率无差异,淋巴结获取数相似。

核心结论

  • 胸腔镜肺叶切除治疗非小细胞肺癌安全可靠,在手术时间和术中出血方面可能优于腋下开胸。

研究设计与样本

  • 随机对照试验,在五家三级医院开展,纳入18至75岁临床早期非小细胞肺癌患者,随机分为胸腔镜组和腋下开胸组,标准术式为肺叶切除加纵隔淋巴结清扫。
  • 2008年至2014年共招募508例患者,425例符合分析条件(胸腔镜组215例,腋下开胸组210例)。

主要发现

  • 胸腔镜组手术时间中位数150分钟,显著短于腋下开胸组的166分钟(p=0.009)。
  • 胸腔镜组术中出血量少于腋下开胸组(p=0.001)。
  • 两组术后胸腔引流、住院时间、并发症发生率和死亡率无差异。
  • 胸腔镜组1例、腋下开胸组5例发现癌残留切缘(p=0.128)。
  • 两种手术方式的淋巴结获取数相似(p=0.389)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Safety and short-term efficacy of video-assisted thoracoscopic surgery (VATS) for early-stage non-small lung cancer (NSCLC) has been demonstrated by observational studies previously. However, these outcomes have never been verified by a large randomized controlled trial (RCT). The aim of our RCT was to confirm that VATS is not inferior or even superior to open operation for early-stage NSCLC in terms of short-term and oncologic efficacy. METHODS: The trial was undertaken at five tertiary hospitals. Patients aged between 18 and 75 years with clinically early-stage NSCLC were randomly assigned to the VATS and axillary thoracotomy groups. Lobectomy plus mediastinal lymph node dissection was standard surgical intervention. Because patients continue to be followed up for oncologic outcome, the short-term perioperative outcomes would be reported here. RESULTS: Between 2008 and 2014, 508 patients were recruited and 425 were eligible for analyses (215 VATS and 210 axillary thoracotomy). Eight VATS procedures were converted to open operation intraoperatively (3.72%). Median operation time with VATS was significantly less than axillary thoracotomy (150 versus 166 minutes, p = 0.009). In addition, VATS was associated with less intraoperative blood loss (p = 0.001). There was no difference for postoperative pleural drainage, length of hospitalization, and rates of morbidity and mortality. Cancer residual margins were found in 1 patient with VATS and 5 with axillary thoracotomy (p = 0.128). The yield of lymph nodes from either surgical approach was similar (p = 0.389). CONCLUSIONS: Our study demonstrates that VATS lobectomy is safe and reliable to treat NSCLCs, and it may be superior to axillary thoracotomy for operation time and intraoperative blood loss. ClinicalTrials.gov identifier: NCT01102517.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Long H, Tan Q, Luo Q, et al. Thoracoscopic Surgery Versus Thoracotomy for Lung Cancer: Short-Term Outcomes of a Randomized Trial. Ann Thorac Surg. 2017. PMID: 29198623. doi:10.1016/j.athoracsur.2017.08.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。